Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Identifying the location of the drug binding site(s) in P-glycoprotein

dc.contributor.authorMittra, Ritu
dc.date.accessioned2022-03-03T04:10:42Z
dc.date.available2022-03-03T04:10:42Z
dc.date.issued2022
dc.description.abstractP-glycoprotein (P-gp), an ABC transporter protein, is characterized by its ability to recognize, bind, and efflux over 300 chemically and structurally unrelated compounds. P-gp overexpression in cancer cells confers multidrug resistance (MDR) by preventing sufficient accumulation of anticancer drugs within the cell, thus avoiding their cytotoxic effects. P-gp harnesses the energy from ATP hydrolysis to translocate substrates across the plasma membrane against a concentration gradient. Biochemical and structural investigations have identified the presence of a large aqueous central cavity which is likely the location for the drug binding sites (DBSs). The substrate polyspecificity displayed by P-gp is imparted by the existence of at least four pharmacologically distinct DBSs located within the transmembrane domain (TMD). However, whether these sites are spatially distinct from each other was not clear. The current investigation has identified several key contact residues of four pharmacologically distinct substrates/modulators of P-gp (nicardipine, vinblastine, rhodamine 123, and paclitaxel), known to bind at the four identified sites. Seven residues in various TMDs were mutated to a cysteine. Biochemical assays using purified, reconstituted P-gp expressing each mutant isoform was used to identify which contact residues were implicated in the binding of each drug. For rhodamine 123 binding, the identified contact residues were located within the central cavity of P-gp. However, for vinblastine, paclitaxel, and nicardipine, the implicated contact residues were located at the lipid-protein interface rather than the central cavity. A key residue (F978) located within the central cavity is believed to be involved in the interdomain communication between the TMDs and the nucleotide binding domains (NBD; site of ATP hydrolysis). Collectively, data presented here suggests the existence of at least four spatially distinct drug binding sites that are connected by a single translocation pore in the central cavity.
dc.identifier.urihttp://hdl.handle.net/1885/261640
dc.language.isoen_AU
dc.titleIdentifying the location of the drug binding site(s) in P-glycoprotein
dc.typeThesis (PhD)
local.contributor.affiliationResearch School of Biology, ANU College of Science, The Australian National University
local.contributor.supervisorCallaghan, Richard
local.identifier.doi10.25911/WGJW-9Z16
local.identifier.proquestNo
local.mintdoimint
local.thesisANUonly.authora866d6b3-b820-46ff-b7d5-1f9f1e3de216
local.thesisANUonly.key77dcc745-ef8a-760d-9acc-361ab934e2d5
local.thesisANUonly.title000000014508_TC_1

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
RMittra PhD Thesis 2022.pdf
Size:
2.14 MB
Format:
Adobe Portable Document Format
Description:
Thesis Material